CHICAGO, IL, May 31 /CNW Telbec/ - New data presented today at ASCO in Chicago showed that Zometa(*) (zoledronic acid) offered a significant anticancer benefit for premenopausal women with hormone-sensitive, early-stage breast cancer. The study found that Zometa(*) when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death.
Study Investigators from the Austrian Breast & Colorectal Cancer Study Group (ABCSG) announced the findings during a plenary presentation today at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).
According to the World Health Organization (WHO), each year approximately 500,000 women die worldwide because their breast cancer has returned or spread. Moreover, the incidence of breast cancer has been rising in recent decades.
Zometa(*) is currently indicated in Canada for the treatment of Tumour-Induced Hypercalcemia following adequate saline rehydration and for the treatment of patients with documented bone metastases from solid tumours (including prostate cancer, breast cancer, lung cancer, renal cell carcinoma and other solid tumours) and of patients with osteolytic lesions of multiple myeloma in conjunction with standard care in order to prevent or delay potential complications from the bone lesions. For complete prescribing information, please visit www.novartis.ca
The following expert is available by phone for interviews to provide Canadian perspective on these data.
Dr Kathy Pritchard, Medical Oncologist, Sunnybrook Odette Cancer Centre, Toronto (Ontario)
ZOMETA(*) is a registered trademark.
For further information: or to book an interview, please contact: Dana Cooper, Mobile (732) 239-6664, on site at ASCO dana@dcoopercommunications.com; Silvie Letendre, Novartis Pharmaceuticals Canada, Mobile (514) 449-7872, Silvie.letendre@novartis.com
